"10.1371_journal.pone.0027463","plos one","2011-11-15T00:00:00Z","Viktor von Wyl; Sara Gianella; Marek Fischer; Barbara Niederoest; Herbert Kuster; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F G端nthard; the Swiss HIV Cohort Study (SHCS)","Division of Infectious Diseases and Hospital Epidemiology, University Hospital Z端rich, University of Z端rich, Z端rich, Switzerland; Research Department of Infection and Population Health, University College London, London, United Kingdom; Division of Infectious Diseases, School of Medicine, University of California San Diego, La Jolla, California, United States of America; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Lausanne, Lausanne, Switzerland; University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland; Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland; Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland","Conceived and designed the experiments: VvW SG MF BJ HFG. Performed the experiments: SG MF BJ HFG BN HK. Analyzed the data: VvW SG MF HFG. Wrote the paper: VvW SG MF BN HK MB AR EB BH RW HFG PV BJ MC. Enrolled Patients: MB AR EB BH RW PV MC HFG.","The authors delcare the following competing interest: HFG has been an advisor and consultant for GlaxoSmithKline (GSK), Abbott, Novartis, Boehringer Ingelheim, Roche, Tibotec, and Bristol-Myers Squibb (BMS) and has received unrestricted research and educational grants from Roche, Abbott, BMS, GSK, Tibotec, and Merck Sharp & Dohme (MSD) (all money to the institution). SY has participated in advisory boards of BMS and Tibotec and has received travel grants from GSK and MSD. MC has received travel grants from Abbott, Boehringer Ingelheim, and Gilead. EB has been an advisor and consultant for Gilead and Abbott, has been a member of an advisory board of ViiV, Gilead, Tibotec, Pfitzer, and MSD, and has received research grants from Gilead and Abbott as well as travel grants from BMS, Gilead, ViiV, MSD, Abbott, and Tibotec. PV has been a member of an advisory board of MSD, Tibotec, Gilead, and ViiV and has received payment for lectures from Gilead, Tibotec, and GSK. All the unrestricted research grants do not relate to the current study. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. All other authors report no potential conflicts.","2011","11","Viktor von Wyl","VVW",15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
